Drug Profile

RECCE 111

Alternative Names: R-111; RECCE-111

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Recce Pharmaceuticals
Class Antibacterials
Mechanism of Action Bacterial protein inhibitors; Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Streptococcal infections

Most Recent Events

28 May 2025 No recent reports of development identified for preclinical development in Streptococcal-infections in Australia (IV)
07 Feb 2024 Recce Pharmaceuticals signs a Memorandum of Understanding (MoU) with PT Etana Biotechnologies Indonesia for the clinical development of RECCE 111 in Indonesia
01 Apr 2021 Preclinical trials in Streptococcal infections in Australia (IV) before April 2021

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com